---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-23-000097"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:16:34.708740+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences reaffirms FY2023 revenue guidance of $170-180M and 2025 targets

## Summary
- Reaffirms FY2023 total revenue guidance of $170-$180M.
- Reaffirms 2025 total revenue target of $255-$330M.
- Reaffirms target to achieve net operating cash flow positivity by 2025.

## SEC filing metadata
- accession: 0001447362-23-000097
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000097/0001447362-23-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000097/cstl-20230605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-23-000097
- JSON: https://secwatch.observer/filing/0001447362-23-000097.json
- Plain text: https://secwatch.observer/filing/0001447362-23-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.